BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 8:45 am ET. The presentation will be accessible via a live and archived webcast on the investors section of the company's website at ir.biostemtechnologies.com.
This event is significant for BioStem as it provides a platform to communicate its strategic direction and product portfolio to a broad audience of healthcare investors. The company leverages proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—to preserve the natural properties of perinatal tissues, which are used by clinicians across various specialties. Its quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).
The announcement comes at a time when the regenerative medicine sector is gaining traction, with increasing demand for advanced allograft solutions. BioStem’s portfolio includes brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™, which are utilized in wound care, surgical repair, and other clinical applications. The company’s participation in the Needham conference may attract potential partners and investors interested in its growth trajectory and clinical research initiatives.
BioStem’s presence at a major healthcare conference highlights its commitment to expanding its national commercial footprint and advancing innovation in regenerative medicine. The webcast will allow stakeholders to hear directly from management about recent developments and future plans. For more information about the company, visit biostemtechnologies.com.
